Chinese Chip Stocks Drop as U.S. Considers Allowing Nvidia to Sell H200 Chips to China

U.S. officials are reportedly weighing easing export controls to allow Nvidia to sell its more powerful H200 AI chips to China, a move that would undercut domestic Chinese chipmakers (SMIC, Hua Hong, Cambricon, ASMPT) and could reduce Beijing's push for self-reliance in AI hardware. The H200—roughly twice the power of the H20 and with nearly double HBM and ~40% faster memory than the H100—comes amid Nvidia's record fiscal Q3 and strong outlook; TipRanks shows a Strong Buy consensus for NVDA (39 Buys, 1 Hold, 1 Sell) with an average price target of $257.33 (implying ~43.9% upside) and YTD share gains of ~33.2%. Policymakers and lawmakers remain divided, and proposed legislation (GAIN AI Act) could restrict exports until domestic customer needs are met, leaving the final market impact uncertain.

Analysis

Market structure will tilt toward Nvidia and US AI-infrastructure suppliers while eroding pricing power and near-term revenue growth for Chinese design/foundry/assembly players (SMIC, Hua Hong, Cambricon, ASMPT). Expect Nvidia to consolidate share in high-end training/inference, allowing it to extend ASP premiums for 6–12 months even as marginal supply into China tempers spot tightness for HBM and datacenter capacity.

Key risks cluster around regulatory reversals and geopolitical spillovers: a Congressional restriction or Beijing countermeasures could materialize within 30–90 days and flip sentiment violently. Second-order effects include accelerated China CAPEX for domestic fabs and equipment procurement (benefiting ASML/LRCX/KLAC indirectly) that could re-rate supply-chain capex over 12–36 months.

Trade opportunities favor asymmetric, defined-risk exposure to NVDA while shorting vulnerable Chinese chip franchises; implied vol in NVDA will compress on clarity, making calendar/vertical spreads preferable to naked longs. Cross-asset: expect widening credit spreads for China tech, modest RMB weakness vs USD (1–3% move), and a short-term bump in HBM sell-off risk; price in increased options skew for China semis.

Consensus misses the speed of China’s policy reaction and the durability of US political risk; markets may underprice a medium-term scenario where China doubles down on subsidies and capacity, which would reduce dependency on US chips in 18–36 months. Conversely, near-term relief for NVDA could be capped by legal and compliance frictions that keep distribution limited and margins protected but not unlimited.

Key Decisions for Investors

• Establish a 2–3% net long in NVDA (NVDA) using a 6–9 month call spread: buy ATM 6-month calls and sell 25% OTM calls to target ~20–40% upside while capping theta; size at 2–3% portfolio risk exposure and trim on +30% realized move or final Commerce rule publication (target date 30–60 days).
• Initiate a 1–2% short exposure to Chinese wafer/packagers: short SMIC (0981.HK) or equivalent ADR/ETF, or buy 3–6 month puts if available, sizing to offset ~30–50% of NVDA long delta as a pair trade to capture relative weakness while regulatory clarity plays out.
• Buy 6–12 month call LEAPs on ASML (ASML) or Lam Research (LRCX) 1% position if shares dip >8% on headline volatility — hedge for an 18–36 month Chinese capex acceleration thesis; sell 1–2 month front-month calls against position after a 15% move to monetize IV compression.
• Hedge FX and credit: purchase a 1–2% notional USD/CNH forward or call to protect against RMB weakness and reduce Chinese credit exposure by underweighting China tech credit by 2–3% of fixed-income allocation; increase cash or Treasuries if the GAIN AI Act passes or a senate vote is scheduled within 30 days.